GILD Jun 2024 75.000 call
| Previous Close | 0.1100 |
| Open | 0.4000 |
| Bid | 0.1300 |
| Ask | 0.1700 |
| Strike | 75.00 |
| Expire Date | 2024-06-28 |
| Day's Range | 0.0900 - 0.6900 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 974 |
- Yahoo Finance Video
US indexes open mixed, pharmaceutical stocks climb: Morning Brief
On today's episode of Morning Brief, hosts Brad Smith and Madison Mills analyze the market open and break down the biggest stories of the trading week. The major indexes (^DJI, ^IXIC, ^GSPC) opened mixed in Friday's session, with the Dow Jones Industrial Average leading gains early in the trading day. Nvidia's (NVDA) reign as the US's most valuable publicly traded company was brief. The semiconductor giant shed $118 billion in market capitalization, allowing Microsoft (MSFT) to reclaim the top spot. Moor Insights & Strategy founder, CEO, and chief analyst Patrick Moorhead emphasizes that Nvidia's continued dominance hinges on sustained enterprise demand for its offerings. If customers stop buying Nvidia's offerings, he warns, "then this whole gravy train comes to a screeching halt." Wells Fargo Investment Institute senior global market strategist Scott Wren notes that while the computer services and technology sectors are currently "very highly valued, very momentum driven," investors should consider trimming some of their gains in these areas and reallocating into sectors like industrials, energy, and healthcare. The pharmaceutical and biotech sectors are making major moves as Sarepta (SRPT) received expanded approval from the Food and Drug Administration for its muscular dystrophy drug, and Gilead (GILD) saw encouraging results from its twice-yearly shot to prevent HIV. Meanwhile, Oppenheimer has upgraded Nike (NKE) from Perform to Outperform and raised its price target from $110 to $120. Meta (META) also received a bullish call, as KeyBanc raised its price target from $475 to $540, citing sustained advertising momentum. Keybanc Managing Director Justin Patterson explains that Meta's ad revenue is "accelerating sequentially" despite intensifying competition, indicating that "demand for Meta's advertisements remains very high." This post was written by Melanie Riehl
Investor's Business DailyWhy A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock
While Gilead Sciences has not been a leader this year, it has led bull runs in the past. In a Thursday story published on Investors.com, Gilead got highlighted for extraordinary results with one of its newest preventive drugs managing HIV infections. This led to a surge in the price of GILD stock and a recapture of the 50-day moving average.
ZacksGilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
Gilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. Shares gain.
